Clinical Trials Logo

Clinical Trial Summary

The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01300468
Study type Interventional
Source Nerviano Medical Sciences
Contact
Status Completed
Phase Phase 1
Start date April 2006
Completion date December 2009

See also
  Status Clinical Trial Phase
Completed NCT02648490 - An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Phase 1
Recruiting NCT01226407 - Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile Phase 1
Withdrawn NCT04891718 - CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia Early Phase 1
Completed NCT01447732 - Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT04958226 - A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours Phase 1
Completed NCT04121910 - A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole Phase 1
Terminated NCT01219543 - A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. Phase 1
Completed NCT01627990 - Nivestimâ„¢ in Treatment of Malignant Diseases N/A
Terminated NCT01516645 - Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01489826 - A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours Phase 1
Unknown status NCT01046461 - Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer Phase 2
Completed NCT02086721 - Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor Phase 1
Active, not recruiting NCT00467779 - Study of GDC-0973/XL518 in Patients With Solid Tumors Phase 1